GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Change In Receivables

Betta Pharmaceuticals Co (SZSE:300558) Change In Receivables : ¥0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Change In Receivables?

Betta Pharmaceuticals Co's change in receivables for the quarter that ended in Mar. 2025 was ¥0 Mil. It means Betta Pharmaceuticals Co's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

Betta Pharmaceuticals Co's change in receivables for the fiscal year that ended in Dec. 2024 was ¥157 Mil. It means Betta Pharmaceuticals Co's Accounts Receivable declined by ¥157 Mil from Dec. 2023 to Dec. 2024 .

Betta Pharmaceuticals Co's Accounts Receivable for the quarter that ended in Mar. 2025 was ¥159 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Betta Pharmaceuticals Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 15.76.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Betta Pharmaceuticals Co's liquidation value for the three months ended in Mar. 2025 was ¥-2,626 Mil.


Betta Pharmaceuticals Co Change In Receivables Historical Data

The historical data trend for Betta Pharmaceuticals Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Change In Receivables Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.65 -181.60 -198.29 174.20 156.53

Betta Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Betta Pharmaceuticals Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Betta Pharmaceuticals Co  (SZSE:300558) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Betta Pharmaceuticals Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=158.517/917.555*91
=15.76

2. In Ben Graham's calculation of liquidation value, Betta Pharmaceuticals Co's accounts receivable are only considered to be worth 75% of book value:

Betta Pharmaceuticals Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=597.767-3494.219+0.75 * 158.517+0.5 * 302.96
=-2,626

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Betta Pharmaceuticals Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 355, Xingzhong Road, Economic and Technological Development Zone, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311100
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co Headlines

No Headlines